Capmatinib | Novartis | ||
150 and 200 mg ; Tablet |
Less Than $1000 mn
|
||
None | None | ||
Less Than 5
|
None | ||
None | None | ||
TABRECTA is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test. | |||
Yes
|
Tabrecta | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 |
---|---|---|---|---|---|
******* ******* |